Abbott Laboratories (ABT)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT). Investors who purchased Abbott securities are encouraged to obtain additional information and assist the investigation.


The investigation concerns whether Abbott and certain of its officers and/or directors have violated federal securities laws.

On May 25, 2022, Dr. Robert Califf, the head of the Food and Drug Administration (“FDA”), testified to the Energy and Commerce Subcommittee of the U.S. House of Representatives in connection with the ongoing baby-formula shortage affecting the U.S.  As reported by The New York Times in an article entitled “F.D.A. Chief Details ‘Shocking’ Conditions at Baby Formula Plant”, Dr. Califf “detailed ‘egregiously unsanitary’ conditions” at the Abbott plant in Michigan that was shut down in February, precipitating the shortage crisis.  Dr. Califf testified that “’the inspection results were shocking’” and that “’[w]e had no confidence in integrity of the quality program at the facility[.]’”   


If you are aware of any facts relating to this investigation or purchased Abbott shares you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.